Introduction
============

Hippocampal sclerosis (HS) is a pathological change long-associated with epilepsy and although not specific for syndrome or seizure-type, is particularly associated with mesial temporal lobe epilepsy (TLE) [@b1] from benign [@b2] to drug-resistant types. Evidence suggests it is a relatively common pathology, identified in 25% of all TLE patients on MRI [@b3] and histologically confirmed in 33.6% and 30--40% of surgical [@b1] and *post mortem* (PM) epilepsy cases [@b4],[@b5] respectively. The pathological alterations of HS in epilepsy (HS~E~) are well described [@b6], with consistent patterns of neuronal loss and gliosis centred on the CA1 subfield, with more variable loss from CA4 and other subfields. More recently, the associated pathology involving the dentate gyrus has been better characterized with dispersion of the granule cell layer (GCD) [@b7] and sprouting of the mossy fibre axons [@b8] noted as common alterations. In addition to loss of principal neurones, stereotypical changes to hippocampal interneurons are well documented in surgical series, particularly in the dentate gyrus, including loss and fibre sprouting [@b9]--[@b13]. These alterations to the dentate gyrus, which tend to occur synchronously, are likely influenced by hippocampal seizures and excitability rather than neuronal loss and they have been observed in PM as well as surgical series of patients, where they may be bilateral [@b14].

HS has also been increasingly recognized on imaging and at PM in older and elderly patients, typically in the absence of a seizure history, but in association with memory impairment or dementia (HS~D~). The proposed causes of HS~D~ are heterogenous, and include anoxic-ischaemic injury and neurodegenerative causes [@b15],[@b16]. HS~D~ has recently been linked to TDP-43 associated pathology [@b17] in support of underlying degenerative mechanisms. The prevalence of HS~D~ in non-epilepsy, elderly PM series is around 16% [@b18] and is bilateral in half of the cases [@b16]. The pathological differences between HS~E~ and HS~D~ have not been directly compared, in particular if similar alterations in the dentate gyrus occur. Differences between HS~E~ and HS~D~ would be useful in histopathological evaluation, and may identify distinct mechanisms of cell degeneration, and alterations specific to symptoms, including seizures *vs.* memory loss. The aim of the current study was to compare the dentate gyrus pathology in a series of HS~E~ with HS~D~ PM cases, in particular with regard to the patterns of GCD, mossy fibre sprouting and interneuronal alterations.

Materials and methods
=====================

Cases were selected from the PM archives at the National Hospital for Neurology and Neurosurgery, Queen Square and from the Queen Square Brain Bank, Institute of Neurology, London (details of all cases are available in a supplemental file, Table S1). This study has been approved by the Joint Research Ethics Committee of the Institute of Neurology and appropriate consent was obtained from the patient\'s next of kin. We selected nine cases with bilateral hippocampal sclerosis, as confirmed at PM, from patients with epilepsy (HS~E~). Four patients were male and the average age of onset of epilepsy was 11 years with mean duration of disease of 53 years, and the average age of death was 62 years (range 27--87 years). All the patients had partial epilepsy syndromes, with a diagnosis of TLE in four. We selected cases with low Braak stages [@b5], which included six cases with stage 1 or 2, and three with stage 3. All the patients were residents at the National Society for Epilepsy, Chalfont Centre, UK. For five patients, there was a history of progressive cognitive decline reported in later life [@b5].

We selected 10 cases of patients with Alzheimer\'s disease (AD) and diagnosis of HS~D~, defined as pyramidal cells loss in the hippocampal formation that is out of proportion to the AD neuropathological changes [@b19]. Seven patients were male and the average age of death was 69 years (range 66--78 years). Nine cases were Braak stage 6 and one case Braak stage 5. In addition, we included eight cases with fronto-temporal lobe dementia (FTLD) and a diagnosis of HS~D~, which included four males. The average age at death was 72 years (range 67--78 years) and the diagnosis was FTLD-TDP type C in three cases, type B in one case, type A in two cases, Pick\'s disease in one case and unspecified in one case [@b20]. In only one patient with AD was there a history of seizure events following onset of dementia, and in no case was epilepsy documented early in life. In addition, 11 control cases were selected with no history of AD or epilepsy; four were male and the mean age was 55 years (range 36--68 years).

In all cases, one hemisphere was selected and a block taken from the hippocampal body at the level best representing the HS pathology as evaluated on H&E and cresyl violet/luxol fast blue preparations. Sections were cut at 7 μm thickness (and 14 μm for dynorphin labelling) for immunohistochemistry. In brief, endogenous peroxidase activity was blocked with 3% hydrogen peroxide (VWR International, Pennsylvania, USA), sections were microwaved for 15 min in antigen retrieval masking buffer (Vector, Burlingame, CA, USA) and washed in phosphate buffered saline (PBS, Oxiod, Hampshire, UK). The primary antibodies, anti-neuropeptide Y (NPY, 1:4000; Sigma, USA), anti-calretinin (1:4000; Swant, Switzerland), anti-calbindin (1:10 000; Swant), anti-dynorphin (1:50; AbD Serotec, UK), GFAP (1:1500; Dako, Cambridge, UK) and GFAP-δ (1:5000; Chemicon International, Temecula, CA, USA) were diluted in Dako antibody diluent (Dako, Glostrup, Denmark) and applied overnight. DAKO envision horse radish peroxidase (HRP, Dako) was used to detect labelling. Nuclei were counterstained with Haematoxylin (VWR International). The catalysed signal amplification was employed for the dynorphin staining (see Liu *et al*. [@b21] for detailed protocol).

In addition, double labelling was performed on selected HS~D~ cases to further characterize NPY-immunopositive Hirano bodies. In brief, sections were initially incubated overnight with anti-MAP2 (1:750; Sigma), AT8 (1:1200; Autogen Bioclear, UK), or SMI 31 (1:1000; Sternberger Monoclonal Incorporation, USA) antibodies. On the following day, Dako Envision EnVision™ HRP solution was applied for 30 min before fluorescein-labelled antibody in tyramide signal amplification (TSA) buffer (1:500; Perkin Elmer, UK) was applied for 8 min. The TSA system is a sensitive detection system that has been used in previous studies on PM human tissue [@b22],[@b23]. Sections were thoroughly washed before anti-NPY antibodies (1:4000) were applied overnight. Rhodamine-labelled antibody in TSA buffer (1:500; Perkin Elmer) was incubated on sections for 8 min at room temperature, before sections were coverslipped in DAPI-mounting media (Vector). Immunofluorescent-labelled sections were viewed under a confocal laser scanning microscope (Zeiss LSM 710) equipped with blue diode, argon and helium/neon lasers.

Qualitative assessment
----------------------

In each case, the degree of hippocampal neuronal loss in CA4 and CA1 and the pattern of granule cell dispersion were assessed on the H&E section and graded (Table [1](#tbl1){ref-type="table"}) in addition to the distribution of astrocytic gliosis on GFAP and delta-GFAP sections. The presence of mossy fibre sprouting (MFS) and the expression patterns of calbindin, calretinin and NPY in the dentate gyrus (in particular loss of neuronal expression and abnormal fibre sprouting) were assessed and graded as previously described and validated in studies of HS~E~ (Table [1](#tbl1){ref-type="table"}) [@b12]--[@b14],[@b23]. The grading was carried out independently by two observers with good agreement (kappa scores between 0.65 and 0.74 for the four markers), and agreement reached on all cases following a joint review.

###### 

Grading system for assessment of neuronal loss and evaluation of mossy fibre sprouting (MFS) on dynorphin staining and alterations to inhibitory neuronal markers in the dentate gyrus

  Grade            0                                                                                                      1                                                                                  2                                                                              3
  ---------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------
  CA1              No neuronal loss                                                                                       Neuronal loss present but incomplete (∼50--75%)                                    Majority of neurones lost (\>75%)                                              
  CA4              No neuronal loss                                                                                       Neuronal loss present but incomplete (∼50--75%)                                    Majority of neurones lost (\>75%)                                              
  GCD              Normal granule cell layer                                                                              Mild dispersion                                                                    Severe dispersion                                                              
  Dynorphin        Normal pattern: labelling of the mossy fibre pathway in CA4 and CA3                                    MFS in IML                                                                         MFS in IML and OML                                                             
  Neuropeptide Y   Normal pattern: radial axonal sprouts inconspicuous & horizontal axonal network in OML \> IML          Few radial axonal sprouts in IML but gradient between IML and OML still visible.   Radial axonal sprouts prominent and gradient between IML and OML not visible   As in grade 2 but radial axonal sprouts through IML OML and SGZ
  Calretinin       Normal pattern: dense band of axons in immediate SGZ and IML                                           Loss of SGZ labelling                                                              Diminution of dense band of axons in SGZ and IML and axonal sprouts            As in grade 2 but extensive axonal sprouts in IML and OML
  Calbindin        Normal pattern: strong expression in granule cells, apical dendrites and mossy fibres in CA4 and CA3   Patchy loss of expression in granule cells                                         Majority of granule cells negative                                             Loss of expression predominates in basal cell layer

These grading schemes are based on previously used and validated scoring schemes [@b12]--[@b14],[@b23]. Granule cell depletion was not recorded in this system. GCD, granule cell dispersion; MFS, mossy fibre sprouting; IML, internal molecular layer; OML, outer molecular layer; SGZ, subgranular zone.

Quantitative assessment
-----------------------

In calbindin immunolabelled sections, quantitative analysis of the distribution of positive cell labelling was carried out as previously described [@b12]. In brief, images were captured at ×10 magnification on calbindin stained sections with a Zeiss Axio microscope (Zeiss, Cambridge, UK). Up to 8 fields along the dentate gyrus were selected per case, avoiding angles and curvatures. Using Image-Pro software (version 6.3, Media Cybernetics, UK), the perpendicular distances of cells (μm) in the dentate gyrus was measured from a line drawn along the basal granule cell layer in each image. This was repeated for positively and negatively stained granule cells in each region. The mean distance for each group of cells and the differences between these means was recorded.

Statistical analysis of data between groups was carried out with SPSS (IBM, version 20) using the Mann-Whitney test and Pearson\'s correlation.

Results
=======

Patterns of HS and GCD
----------------------

Neuronal loss in the HS~D~ group was predominantly centred on CA1, rather than CA4 subfield, compared with HS~E~ cases (Table S1, Table [2](#tbl2){ref-type="table"}; Figure [1](#fig01){ref-type="fig"}**A**); a significant difference in the severity of neuronal loss in CA4, but not CA1, was shown for all HS~D~ (AD + FTLD) compared to HS~E~ (*P* \< 0.0001). Additionally, in four HS~D~ cases the neuronal loss in CA1 continued into the subiculum, whereas in HS~E~ cases, there was an abrupt transition between neuronal loss in CA1 and the spared subiculum (Figure [1](#fig01){ref-type="fig"}**B**). In one HS~D~ case, the neuronal loss was restricted to a segment of CA1. GCD was less pronounced in the HS~D~ group (Table [2](#tbl2){ref-type="table"}) with over 80% showing no dispersion, compared to 44% with no dispersion in the HS~E~ group (Figure [1](#fig01){ref-type="fig"}**A**,**B**). GFAP in HS~E~ (Figure [1](#fig01){ref-type="fig"}**D**) showed a typical pattern of dense fibrous gliosis relatively restricted to CA1 and CA4, sparing CA2 and subiculum, with radial glial fibres in the dentate gyrus. In HS~D~ cases patterns of gliosis were more variable between subfields, as previously noted [@b24], but in the majority of cases a cellular astrocytosis was equally or more pronounced in the subiculum than CA1, and radial gliosis was less consistently present in the dentate gyrus. In GFAP-δ immunostained sections in both HS~D~ and HS~E~ prominent reactive glia were noted in the subgranular zone and CA4 to a greater extent than CA1, as previously described in HS~E~ [@b25] (Figure [1](#fig01){ref-type="fig"}**C**,**D**); delta-GFAP was therefore less discriminatory than GFAP in the evaluation of HS types.

![Comparison of hippocampal pathology in hippocampal sclerosis with dementia (HS~D~; **A**,**C**,**E**,**G**) and with epilepsy (HS~E~; **B**,**D**,**F**,**H**). In both HS~D~ and HS~E~ neuronal loss in CA1 is the predominant finding (**A**,**B**); dispersion of the granule cells is more commonly a feature accompanying HS~E~ (**B**, insert) than HS~D~ (**A**, insert). Astrocytic gliosis with GFAP immunostaining is more variable and cellular, but can be extensive in HS~D~ and can be equally severe in the subiculum (SC) as in CA1 (**C**); in HS~E~ there is abrupt, subfield-specific fibrous gliosis demarcating CA1 and CA4 with sparing of the subiculum (SC) and CA2 region. With delta-GFAP immunostaining in HS~D~ and HS~E~ (insets in **C**,**D** respectively), scattered multi-polar glial cells are prominent in CA4 and near the basal granule cell layer. (**E**) Normal calbindin staining is shown in the hippocampus with labelling of granule cell layer, apical dendrites in the molecular layer (ML) and axonal projection in the mossy fibre pathway to CA4 and CA3. (**F**) In HS~E~ loss of calbindin expression in the granule cells and their processes is a frequent finding but with residual interneurones normally labelling (arrow). (**G**) A normal dynorphin immunostaining pattern in HS~D~ highlighting the mossy fibre pathway and (**H**) mossy fibre sprouting in the molecular layer (ML) in HS~E~. Bar in all approximately equivalent to 2500 μm.](nan0040-0177-f1){#fig01}

###### 

Results of hippocampal pathology, shown as percentage of cases with each grade in the patient groups (see text and Table [1](#tbl1){ref-type="table"} for details of grading scheme)

  Grade                                           CA1          CA4             Dynorphin    Calbindin     Calretinin    Neuropeptide Y   GCD                                                                                                                      
  ----------------------------------------------- ------------ --------------- ------------ ------------- ------------- ---------------- ------------ ------- ------- ------- ----- ----- ----- ------ ----- ----- ----- ------- ----- ----- ------- ------ ----- -----
  HS~E~ (*n* = 9)                                 0%           33%             67%          11%           44%           44%              37.5%        12.5%   50%     0%      11%   33%   56%   29%    14%   0%    57%   12.5%   25%   0%    62.5%   44%    11%   45%
  HS~D~ AD (*n* = 10)                             6%           50%             44%          83%           17%           0%               90%          10%     0%      30%     50%   0%    20%   60%    20%   20%   0%    20%     60%   20%   0%      83%    17%   0%
  HS~D~ FTLD (*n* = 8)                            71%          29%             0%           62.5%         25%           12.5%            0%           75%     12.5%   12.5%   0%    57%   43%   0%     0%                                                         
  Control cases (*n* = 11)                        91%          9%              0%           91%           9%            0%               100%         0%      0%      67%     22%   11%   0%    100%   0%    0%    0%    100%    0%    0%    0%      100%   0%    0%
  Significance[\*](#tf2-1){ref-type="table-fn"}   *P* = 0.05   *P* \< 0.0001   *P* = 0.01   *P* = 0.005   *P* = 0.002   *P* = 0.01       *P* = 0.05                                                                                                               

*n* = the number of cases in each group. With some antibodies, occasional cases were not included in the analysis due to repeated technical problems. ^\*^Significance is shown as between grades in all HS~E~ and HS~D~ (AD + FTLD) groups using the Mann--Whitney test. HS~E~, hippocampal sclerosis with epilepsy; HS~D~, hippocampal sclerosis with dementia; AD, Alzheimer\'s disease; FTLD, fronto-temporal lobe dementia; GCD, granule cell dispersion.

### Dynorphin (Figure [1](#fig01){ref-type="fig"}**G,H**; Figure [2](#fig02){ref-type="fig"}**A--C**)

![Dentate gyrus alterations in hippocampal sclerosis in epilepsy (HS~E~) and dementia (HS~D~) and control (cont). Dynorphin: (**A**) In the majority of HS~D~ cases a normal mossy fibre pathway (grade 0) was visible with labelling of axons in CA4 and no immunopositivity visible in the molecular layer. (**B**) Occasional focal sprouting of dynorphin-positive fibres was noted in the inner molecular layer (IML) in three HS~D,~ (grade 1). (**C**) Severe and extensive mossy fibre sprouting (grade 2) in the molecular layer (IML) was seen only in HS~E~ cases. Calbindin: (**D**) Normal expression in granule cells, dendrites and mossy fibre axons was noted in controls and HS~D~ cases (grade 0) with, (**E**) loss of expression in some cases (grade 2). (**F**) Loss of expression restricted to basal granule cells (grade 3) was noted in three HS~D~ cases without dispersion and (**G**) was the commonest pattern in HS~E~ cases with granule cell dispersion. Calretinin: (**H**) a normal pattern of calretinin labelling of the axonal plexus on either side of the granule cell layer is shown in controls (grade 0). (**I**) Loss of the plexus in the subgranular zone (grade I) and (**J**) sprouting of fibres in the IML (grade 2) was seen in some HS~D~ cases. (**K**) In HS~E~, marked sprouting of fibres in the IML was a prominent finding (grade 3). Neuropeptide Y: (**L**) Normal pattern (grade 0) with an axonal plexus in the outer molecular layer (OML) was seen in controls. Progressively more prominent sprouting of fibres was noted in the inner molecular layer (IML) in HS~D~ cases (grade 1 to 2; **I**,**J**). (**O**) Extensive NPY fibre sprouting through the molecular layer (grade 3) was only observed in HS~E.~ See also Table [1](#tbl1){ref-type="table"} for details of descriptions of grading. Bar is equivalent to 300 μm.](nan0040-0177-f2){#fig02}

In HS~E~, MFS was confirmed in five cases, with grade 2 sprouting observed in four; there was no MFS in any of the controls. Dynorphin immunolabelling confirmed a normal mossy fibre pathway in the majority of HS~D~ cases, with only three cases showing MFS, one in the AD group (grade 1) and two in the FTLD group (grade 1) (Table S1, Table [2](#tbl2){ref-type="table"}); no grade 2 MFS was noted in the HS~D~ group. Of note, in contrast to the loss of dynorphin labelling of axons and terminals in the normal mossy fibre projection to CA4 and CA3 in HS~E~ cases with MFS, in HS~D~ these pathways appeared better preserved. In addition, in one AD case, plaque-like aggregates of dynorphin were noted in the CA4 region (Figure [3](#fig03){ref-type="fig"}**A**), likely corresponding to neuritic plaques.

![(**A**) Dynorphin occasionally labelled neuritic plaques in CA4 in Alzheimer\'s disease cases. (**B**) Sprouting of calbindin-positive fibres was noted in the dentate gyrus in HS~E~ cases but not in HS~D~. (**C**) Hirano bodies were noted in CA1 in the control and HS~D~ groups but not in HS~E~ on H&E preparations. (**D**) NPY showed intense labelling of numerous Hirano body-like structures in CA1 in HS~D~ in addition to labelling axons and residual interneurons in this region. They were seen in proximity to negatively labelled pyramidal neurones (**D**) or free in the neuropil (**E**) with occasional body showing a tail like process (arrowhead in **E**). (**F**) In HS~E~ cases, only interneurons and extensive fibre networks were labelled in CA1 with NPY. (**G**) Weaker labelling of Hirano bodies was noted with calretinin. (**H**) Con-focal microscopy showed no co-localization of NPY-positive Hirano-like bodies with AT8 positive pyramidal cells in CA1; double-labelling with dendritic marker MAP2 (**I**) showed approximation of NPY Hirano bodies to neuronal process and dendrites. In addition, a peripheral rim of NPY positivity was appreciated in some Hirano bodies with a hollow central core (arrowhead). Bars in **A**,**C**,**D**,**E**,**G** = 75 μm, **B**,**F** = 140 μm, **H** = 20 μm, **I** = 20 μm.](nan0040-0177-f3){#fig03}

### Calbindin (Figure [1](#fig01){ref-type="fig"}**E**,**F**; Figure [2](#fig02){ref-type="fig"}**D**--**G**)

Reduced calbindin expression was noted in the granule cells in all HS~E~ cases, the predominant pattern being grade 3, with loss of expression restricted to the more basal cells, as reported previously [@b12]. In addition, prominent sprouting of calbindin-positive fibres through the dentate gyrus was noted in four cases (Figure [3](#fig03){ref-type="fig"}**B**) as previously described in epilepsy [@b11]. Loss of calbindin was statistically less frequent in HS~D~ (Figure [2](#fig02){ref-type="fig"}**D**--**E**), observed in 10 of the 18 cases (seven from the AD group); Only two cases had a grade 3 pattern with the loss of calbindin in the more basal cells compared to the distal cells (Figure [2](#fig02){ref-type="fig"}**F**), but in contrast to HS~E~ this was not accompanied by GCD (Table [2](#tbl2){ref-type="table"}). Measurements confirmed greater mean differences in the position of positive *vs.* negatively labelled granule cells from the basal layer in HS~E~ than HS~D~ or control groups (mean values 30.2, 10.1 and −3.9 μm respectively; *P* \< 0.05). Sprouting of calbindin-positive axon fibres was not observed in any HS~D~ cases. The loss of calbindin in granule cells was also present in three controls. In all cases with reduced expression of calbindin in the hippocampal granule cells, normal interneuronal staining was preserved in the adjacent cortex.

### Calretinin (Figure [2](#fig02){ref-type="fig"}**H**--**K**)

The predominant pattern in HS~E~ was grade 3 (4 cases), with prominent sprouting of fibres and loss of the normal organization (Table [2](#tbl2){ref-type="table"}, Figure [2](#fig02){ref-type="fig"}**K**). All controls showed a normal calretinin pattern (Figure [2](#fig02){ref-type="fig"}**H**). Abnormal calretinin pattern was seen in six of the 18 HS~D~ cases (grade 2 (three cases) and grade 1 (three cases); 4 in the AD group) (Figure [2](#fig02){ref-type="fig"}**I**--**J**) but no grade 3 patterns were observed. In a further case, loss of calretinin labelling in the dentate gyrus was noted. Calretinin interneurons appeared generally preserved and normal in appearance in the adjacent temporal cortex in AD and FTLD cases.

### Neuropeptide Y (Figure [2](#fig02){ref-type="fig"}**L**--**O**)

The predominant pattern in the HS~E~ was grade 3, with prominent sprouting of fibres through the dentate gyrus (Figure [1](#fig01){ref-type="fig"}**O**); a normal NPY pattern was seen in only one case. Controls all showed a normal NPY pattern. In HS~D~ cases, NPY patterns were abnormal in 11 cases \[grade 2 (two cases) and grade 1 (nine cases)\] (Figure [1](#fig01){ref-type="fig"}**L**--**N**); no grade 3 pattern was observed. Occasional NPY processes were seen within senile plaques (Figure [2](#fig02){ref-type="fig"}**N**).

Statistical analysis confirmed significantly higher grades of reorganization of calbindin, calretinin, NPY and dynorphin labelling in the dentate gyrus in HS~E~ compared to all HS~D~ cases (Table S1 and Table [2](#tbl2){ref-type="table"}). There were strong correlations between calretinin, NPY and dynorphin grades (but not calbindin) in the HS~E~ group (all *P* \< 0.001), but this was less evident in the HS~D~ group (all *P* \> 0.01). In eight cases in the HS~D~ group, abnormal patterns were observed in the dentate gyrus with two or more of the four markers and in two cases (one AD, one FTLD) with all four. In one HS~D~ patient with a history of seizures, grade 1 patterns were seen with calbindin and NPY but dynorphin and calretinin patterns were normal. There were no statistical differences in any of the pathological measures between HS~E~ patients with or without cognitive decline, but the numbers in each group were small; similarly no differences were noted between the HS~D~ AD and FTLD groups.

An additional finding on NPY sections was the prominent labelling of structures resembling Hirano bodies in 12 HS~D~ cases (8 AD, 4 FTLD) (Figure [3](#fig03){ref-type="fig"}**D**--**E**). They were regionally restricted to CA1 sector, not seen in other subfields or the neocortex, and their presence was confirmed on corresponding H&E sections (Figure [3](#fig03){ref-type="fig"}**C**). NPY-positive Hirano bodies were observed adjacent to remaining pyramidal cell somata or 'free' in the neuropil (Figure [3](#fig03){ref-type="fig"}**D**--**E**). NPY-positive processes were visible as a 'tail\'-like extension from some Hirano bodies (Figure [3](#fig03){ref-type="fig"}**E**) and a central unlabelled core was noted for some bodies imparting ring-like structures. In seven cases, Hirano body-like structures were visible on calretinin-labelled sections but not with calbindin or dynorphin labelling (Figure [3](#fig03){ref-type="fig"}**G**). Double-labelling immunofluorescence of NPY with dendritic marker, anti-MAP2, confirmed focal co-localization in some Hirano bodies (Figure [3](#fig03){ref-type="fig"}**I**), whereas others appeared lying adjacent to, but distinct from, phosphorylated tau (AT8)-positive pyramidal cells (Figure [2](#fig02){ref-type="fig"}**H**). We did not see Hirano bodies co-localizing with neurofilament-positive axons (not shown). NPY (or calretinin)-labelled Hirano bodies were not seen with any of the epilepsy cases (even up to age 87 years), where only normal NPY interneurons were observed (Figure [3](#fig03){ref-type="fig"}**F**). NPY-positive Hirano bodies were noted in CA1 in three controls (57--68 years).

Discussion
==========

Hippocampal sclerosis is a generic term used for the description of neuronal loss and gliosis, preferentially involving hippocampal subfields. Although historically associated with epilepsy, there has been increasing recognition in recent years of a similar pathological change arising as a 'pure' lesion in elderly, or in association with a neurodegenerative condition. These different clinical groups of HS have not been directly compared histologically. Identification of different cellular alterations would be helpful in their diagnostic evaluation, would allow a deeper understanding of different mechanisms of cell degeneration that may be operating, and would enable the identification of pathological alterations that correlate with specific clinical symptoms, for example cognitive dysfunction *vs.* hippocampal epileptogenicity.

HS~E~ and HS~D~ may both be bilateral or asymmetrical between hemispheres [@b23],[@b26], with no clear predilection for left or right and may vary in the extent of its longitudinal involvement along the hippocampal axis (Table [3](#tbl3){ref-type="table"}). In this present study we focused on one level of the hippocampal body from each case, representative of the sclerosis, for detailed analysis. We observed differences between HS~D~ and HS~E~ in the distribution of cell loss between subfields at this coronal level. The neuronal loss in HS~D~ predominantly involved CA1 sector, typically extending into the subiculum in several cases, but sparing CA4. This distribution of neuronal loss has been previously reported in studies of HS~D~ [@b17],[@b26]. This contrasts to the classical pattern of atrophy in HS~E~, where CA1 damage is accompanied by CA4 neuronal loss with an abrupt transition between the neuronal loss and gliosis in CA1 and the adjacent well-preserved subiculum [@b1]. We also showed that GCD, a common alteration in HS~E~ [@b27],[@b28], was rare and mild in HS~D~. GCD has been associated with both an early age of onset of seizures and with the severity of CA4 neuronal loss [@b27],[@b29]. An atypical pattern of HS~E~ shows predominant involvement of CA1 only, and has been associated with a later age of onset of seizures [@b30],[@b31]. These observations could indicate an age-dependent vulnerability of the dentate gyrus and CA4, which is spared in older onset HS~E~ and HS~D~ cases.

###### 

Summary of the clinical, pathological and aetiological features that enable the distinction of HS~E~ from HS~D~

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Feature                                      HS in epilepsy (HS~E~)                                                                             HS in dementia and ageing (HS~D~)
  -------------------------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  Clinical context                                                                                                                                

   Typical presentation                        Childhood to young adulthood\                                                                      Adult to the 'oldest-old'\
                                               Seizure syndromes, particularly mTLE                                                               Dementia, cognitive decline.

   Prevalence                                  Surgical epilepsy series ∼35%\                                                                     In elderly between ∼3--24%\
                                               PM epilepsy series ∼30--40%                                                                        'Pure' HS in 23% of dementia cases

  Distribution                                                                                                                                    

   Bilaterality                                Bilateral in ∼48--56% in epilepsy PM series (all syndromes including TLE)                          Bilateral in ∼45--60%

   Longitudinal extent                         Localized or extensive along rostro-caudal length [@b14]                                           Localized or extensive along rostro-caudal length [@b26]

  Pattern of HS                                                                                                                                   

   Distribution of neuronal loss and gliosis   CA1: Typically severe cell loss\                                                                   CA1: Extensive to patchy loss\
                                               Subiculum: Spared\                                                                                 Subiculum: Often cell loss\
                                               CA4/3: Neuronal loss\                                                                              CA4: Spared\
                                               Granule cell dispersion in ∼50%                                                                    Granule cell dispersion less evident

  Circuitry reorganization                                                                                                                        

   Mossy fibre system                          Mossy fibre sprouting typically present and extensive                                              Mossy fibre sprouting usually absent\
                                                                                                                                                  If present mild and focal

   Calbindin expression                        Reduced expression in granule cells, particularly basal cells                                      Reduced expression in granule cells may occur

   NPY expression                              Resistance of CA1 interneurones\                                                                   Loss of CA1 interneurones\
                                               Prominent sprouting in DG                                                                          Mild sprouting in DG in some

   Calretinin                                  Reorganization of DG networks                                                                      Mild reorganization of DG networks may be present

  Patho-mechanisms                                                                                                                                

   Causes of neuronal loss                     Seizure mediated/excitotoxic neuronal injury                                                       Heterogenous causes:\
                                                                                                                                                  'Ageing'\
                                                                                                                                                  Vascular brain injury\
                                                                                                                                                  AD, FTLD\
                                                                                                                                                  Synucleinopathies with HS

   Contribution of TDP-43, ApoE                TDP-43 not identified in surgical unilateral cases [@b17],[@b59] or bilateral HS~E~ at PM [@b5]\   TDP-43 inclusions in up to 93% of pure HS~D~ [@b17],[@b47] [@b26]\
                                               *ApoE* ε4 associated with earlier onset [@b60] in some but not all studies [@b61]                  HS~D~ not associated with *ApoE* ε4 [@b17],[@b47]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

mTLE, mesial temporal lobe epilepsy; DG, dentate gyrus; HS, hippocampal sclerosis; PM, *post mortem*; AD, Alzheimer\'s disease; FTLD, fronto-temporal lobe dementia.

Studies of HS in epilepsy series have focussed on cellular alterations that could render this region hyper-excitable. MFS was first observed in experimental seizure models as an early event [@b8] and has been suggested to be critical to the development of recurrent seizure activity associated with HS~E~, through enhanced excitability and/or synchronization of granule cells. We have previously shown, in a PM series of HS~E~ cases, that MFS can persist into the ninth decade, even with the remission of seizures [@b23]. Therefore, there is an alternative argument that MFS is an epiphenomenon or response to seizures, rather than a primary epileptogenic process. In one HS~D~ patient in the present series in whom occasional clinical seizures were documented, MFS was not present and in other HS~D~ cases, MFS was rare and mild. In elderly patients and those with cognitive decline, partial seizures may be unrecognized [@b32],[@b33] because EEG may not be performed as a routine test, therefore we cannot entirely exclude 'sub-clinical' seizure activity as the mechanism for the focal MFS seen in HS~D~. Notwithstanding, the findings favour the view that severe MFS is linked with hippocampal excitability and is therefore a relatively reliable histological marker for HS~E~.

Alterations to dentate gyrus interneurones have been extensively studied in HS~E~, in surgical and PM tissues. Cell loss, cyto-morphological alterations and axonal sprouting represent the more common findings (for review see [@b34]) and these stereotypical alterations parallel the principal neuronal loss in established cases [@b14]. Interneuronal alterations are not exclusive to HS~E~ associated with mTLE, and can be seen with other epilepsy syndromes [@b14],[@b23]. It is the axonal sprouting of interneurons that is considered a more functionally significant process in relation to network changes, correlating with synaptic re-organization [@b9],[@b11]. These alterations are easily recognized and reliably graded in tissue sections, as in the present study, and sprouting of these inhibitory networks in the dentate gyrus tend to occur in synchrony with the sprouting of excitatory networks (the mossy fibres) [@b23]. We identified significantly more cases with interneuronal sprouting using calretinin and NPY labelling in HS~E~ than HS~D~ cases with more extensive sprouting (corresponding to the higher grades) as well as sprouting of calbindin-positive fibres, which was exclusive to HS~E~ cases.

In previous studies of the hippocampus in AD, a reduction of NPY axons in the dentate gyrus was demonstrated, with clusters or beaded clumps of axons, some associated with neuritic plaques [@b35]. We also confirmed occasional association of NPY fibres in addition to dynorphin fibres, associated with neuritic plaques in AD. In an APP-mutant model of AD, ectopic expression of NPY was shown in granule cells as well as sprouting of NPY fibres in the molecular layer from hilar NPY neurones [@b36]. The authors proposed that this represented amyloid β-mediated neuronal excitatory activity and subsequent re-modelling of inhibitory circuits that resemble alterations in experimental epilepsy models [@b36]. Our study supports the notion that subtle inhibitory neuronal network alterations may occur in HS~D~, similar to HS~E~. As for our observations with MFS in HS~D~, we cannot exclude subclinical epileptic activity or un-recognized seizures and local hippocampal excitability as a cause for these alterations. Furthermore, in eight of the HS~D~ cases with MFS and interneuronal alterations, parallel changes were seen with more than one marker, supporting systematic network re-organization occurring in the dentate gyrus in some cases. A further consideration is that the cellular pathology occurring in HS with neurodegeneration could inhibit these synaptic reorganizational changes that are more profuse in HS with epilepsy.

Loss of calbindin expression in the dentate granule cells has been shown in experimental AD models (human APP transgenic mutant) as well as in PM series [@b37]--[@b39] and correlated with both cognitive deficits and the abundance of amyloid β protein [@b40]. Loss of calbindin in AD was the most frequent abnormality, observed in 70% of AD HS~D~ compared to 37% in the FTLD group in this study. It is also known that an age-related decline of calbindin in granule cells occurs, which has been associated with impaired hippocampal function [@b41], and was noted in three controls in the current study. We recently reported a pattern of calbindin loss from the basal granule cells in HS~E~ associated with early onset of seizures, which was the most prominent pattern also in the present HS~E~ cases. This pattern was noted in only two of the HS~D~ cases. It has been proposed that loss of calbindin causes changes to the intrinsic excitability of granule cells in addition to its roles in memory impairment [@b42]. A reduction of CA4 calretinin positive neurones has also been shown in experimental [@b43] and AD cases [@b44], although less is known about hippocampal interneuronal alterations in FTLD [@b45]. Calretinin axonal networks have not been previously studied in HS~D~; they were mildly altered in a minority of cases in the present series.

HS~D~ may be encountered as a 'pure' or isolated pathology in the elderly, associated with dementia or an amnestic syndrome and in the absence of typical neuronal inclusions associated with AD or FTLD or vascular disease. This may represent a relatively unrecognized cause of dementia, in the oldest age groups [@b46] and is associated with TDP-43 immunoreactive inclusions in the granule cells [@b17],[@b26],[@b47]. The present study was limited by not having 'pure' HS~D~ cases available for comparison to HS~E~. Nevertheless from a practical viewpoint, when HS is encountered at PM examination in the elderly, the pattern of neuronal loss in addition to assessment of any neurodegenerative features (including TDP-43), interneuronal markers and mossy fibre alterations may help to identify the cause of the sclerosis (as summarized in Table [3](#tbl3){ref-type="table"}).

A serendipitous finding in the study was the labelling of Hirano bodies in AD and controls for NPY and, to a lesser extent, calretinin. The origin and physiological function of Hirano bodies in ageing and AD has remained elusive since their first recognition 40 year ago. They are filamentous, paracrystalline inclusions, comprising many proteins including actin, co-filin and alpha-actinin [@b48],[@b49]. The focal overlap of expression of the NPY-positive Hirano body with MAP2 supports the view that some are within dendrites, as previously reported [@b48],[@b50], whereas others may be axonal. It is estimated that CA1 pyramidal cells are supported by 16 types of GABA-ergic neurones [@b51], including NPY interneurons, many forming a connected 'pair' with a single CA1 pyramidal cell [@b52]. NPY-positive interneurons in CA1 are *bi-stratified* cells with axon terminals on the dendritic domains of CA1 pyramidal cells, mediating inhibition via GABA~A~ receptors [@b51],[@b53]. The NPY cell dendrites extend into the stratum oriens and radiatum and, in turn, receive excitatory input from pyramidal cell collaterals.

Previous studies of CA1 NPY interneurones in AD described the most dramatic changes occurring in this subfield with surviving cells bearing shortened dendrites ('dendritic stumps') and damaged thick axons, although labelling of Hirano bodies was not described [@b35],[@b54]. In the PS1/APP transgenic model of AD, loss of NPY-somatostatin co-labelled neurones in CA1 was an early finding, demonstrating a specific vulnerability of these cells in AD, which preceded the pyramidal cell loss [@b55]. In HS~E~ by contrast, relative resistance of NPY-positive interneurons in CA1 has been shown [@b56] in epilepsy models and in human MTLE/HS cases, despite the extensive loss of CA1 pyramidal cells and hilar NPY cells [@b31]. These observations highlight a different time-course for loss of CA1 NPY interneurons in HS~D~ due to AD *vs.* HS~E~. Recent studies have shown PSD-95, a structural protein of excitatory synapses, to label a proportion of Hirano bodies [@b50]; a further study showed co-localization of Hirano bodies with GluR1 and R2 AMPA receptors in the vicinity of pyramidal cells [@b57]. It has been postulated Hirano bodies represent aberrant formation of post-synaptic structures in response to distal synaptic destruction [@b50]. In experimental systems, Hirano bodies have been shown to be both protective against neurodegeneration mediated by tau or APP [@b58] as well as to inhibit normal cellular function [@b49]. One explanation is that Hirano bodies arise in residual NPY neurones in AD as a compensatory, but cellular degenerative response, to the ongoing imbalances between reciprocal inhibitory and excitatory networks as the disease progresses. The potential functional significance of Hirano bodies is therefore of interest and requires further study.

In summary, reorganization of excitatory and inhibitory networks in the dentate gyrus is more typical of HS~E~. Subtle alterations may occur in HS~D~, which could be a result of increased hippocampal excitability, including unrecognized seizure activity. An unexpected finding was the identification of NPY-positive Hirano bodies in HS~D~ but not HS~E~, which may be a consequence of the relative vulnerabilities of interneurons in these conditions.
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